Bildkälla: Stockfoto

Moberg Pharma: European application submitted as planned - Redeye

Redeye views the submittal of the full application of the marketing authorization for MOB-015 as positive, although expected. This application aligns with what the company has indicated earlier with a possible first market approval and launch in 2023.

Redeye views the submittal of the full application of the marketing authorization for MOB-015 as positive, although expected. This application aligns with what the company has indicated earlier with a possible first market approval and launch in 2023.
Börsvärldens nyhetsbrev
ANNONSER